Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease

• Published in: Molecular neurodegeneration Vol. 11; no. 1; p. 3
• Main Authors: Heslegrave, Amanda, Heywood, Wendy, Paterson, Ross, Magdalinou, Nadia, Svensson, Johan, Johansson, Per, Öhrfelt, Annika, Blennow, Kaj, Hardy, John, Schott, Jonathan, Mills, Kevin, Zetterberg, Henrik
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 12.01.2016; BioMed Central
• Subjects: Aged; Aged, 80 and over; Alzheimer Disease - cerebrospinal fluid; Alzheimer Disease - diagnosis; Alzheimer Disease - genetics; Alzheimer's disease; Amyloid beta-Peptides - cerebrospinal fluid; Amyloid beta-Peptides - genetics; Apolipoprotein E4 - cerebrospinal fluid; Apolipoprotein E4 - genetics; Apolipoproteins; Biomarkers - analysis; Biomarkers - cerebrospinal fluid; Care and treatment; Complications and side effects; Development and progression; Enzyme-linked immunosorbent assay; Enzyme-Linked Immunosorbent Assay - methods; Female; Humans; Male; Membrane Glycoproteins - cerebrospinal fluid; Middle Aged; Neurosciences; Neurovetenskaper; Plaque, Amyloid - cerebrospinal fluid; Plaque, Amyloid - genetics; Receptors, Immunologic; Risk Factors; Short Report; tau Proteins - cerebrospinal fluid; tau Proteins - genetics; United States

The discovery that heterozygous missense mutations in the gene encoding triggering receptor expressed on myeloid cells 2 (TREM2) are risk factors for Alzheimer's disease (AD), with only the apolipoprotein E (APOE) ε4 gene allele conferring a higher risk, has led to increased interest in immune...